Create account

Coverage dated October 29, 2026

Merck topped estimates and raised its profit forecast as cancer drug injection took off

Headline from Quartz

Adjusted profit forecast moves to $2.77 to $2.82 a share from $2.66 to $2.76 as Keytruda Qlex sales reach $830 million

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

  1. Bloomberg

    Merck Boosts Profit Forecast as Key Medicines Top Estimates (opens Bloomberg)

    Published

    Bloomberg's feed description

    Merck & Co. raised its full-year profit forecast after third-quarter results topped Wall Street’s expectations, fueled by stronger-than-anticipated sales of cancer blockbuster Keytruda and other newer medicines.

  2. Quartz

    Merck topped estimates and raised its profit forecast as cancer drug injection took off (opens Quartz)

    Published

    Quartz's feed description

    Adjusted profit forecast moves to $2.77 to $2.82 a share from $2.66 to $2.76 as Keytruda Qlex sales reach $830 million

Merck topped estimates and raised its profit forecast as cancer drug injection took off | Since Then